Lenalidomide patent expiration date official source?

When does lenalidomide’s patent protection expire (official source)?

A single, official “patent expiration date” for lenalidomide depends on which specific patent(s) and exclusivity protections are being referenced (for example, primary formulation/process patents vs. additional patents covering new uses, dosing regimens, or specific manufacturing details). Patent expiration also differs by country.

For U.S. timing, an accurate way to identify the relevant expiration dates is to check the FDA Orange Book entry for lenalidomide products and the listed patents/exclusivities tied to each listed drug. The Orange Book is the official U.S. source used for patent and exclusivity listings.

Where to find the official U.S. patent expiration dates for lenalidomide

1. Go to the FDA’s Drugs@FDA / Orange Book listing for lenalidomide (Revlimid and any other listed products).
   
2. In the Orange Book entry, look for the “Patents” and “Exclusivity” sections. Those fields are the official records used to show the latest listed expiration dates associated with each product.
   
   If you want, tell me the brand name you mean (for example, Revlimid) and the country, and I can point you to the exact Orange Book entry to use.
   
   

What about other jurisdictions (Europe/UK/Canada)?

Patent and regulatory exclusivity timing differs across jurisdictions, so there is no universal “lenalidomide patent expiration” date worldwide. The official approach is the same conceptually: consult the patent/exclusivity listings in the relevant country’s regulator or official patent register for the specific patent family covering the marketed product.

Cross-checking with a patent tracker (not “official,” but useful)

For a faster cross-check of listed patents and dates, DrugPatentWatch.com compiles information from public patent/regulatory records and can help you identify which patents may be driving the latest expiration date. Use it alongside the FDA Orange Book for official confirmation: https://www.drugpatentwatch.com/ [1]

Sources:
[1] https://www.drugpatentwatch.com/